TA
NVS icon

TMD & Associates’s Novartis NVS Stock Holding History

TMD & Associates’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-37,450
Closed -$2.44M – 27
2016
Q4 		$2.44M Sell
37,450
-6,338
-14% -$411K 2.12% 18
2016
Q3 		$3.1M Buy
43,788
+850
+2% +$61.9K 2.72% 15
2016
Q2 		$3.17M Buy
42,938
+1,495
+4% +$103K 2.81% 15
2016
Q1 		$2.69M Buy
41,443
+4,944
+14% +$336K 2.66% 13
2015
Q4 		$2.81M Buy
+36,499
New +$2.9M 2.58% 12

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TMD & Associates's NVS Position: Q1 2017 in Review

TMD & Associates sold out of Novartis (NVS) in Q1 2017, closing a stake of 37,450 shares — an estimated $2.44M sold.

TMD & Associates first reported a position in NVS in Q4 2015 and held it in 5 quarters. The position peaked at $3.17M in Q2 2016. 910 funds tracked by Wall St. Rank hold NVS as of Q1 2017.

  • TMD & Associates reported no remaining Novartis position as of Q1 2017 after selling out during the quarter.
  • TMD & Associates sold 37,450 Novartis shares in Q1 2017, an estimated $2.44M.
  • TMD & Associates first reported a position in Novartis in Q4 2015 and held it in 5 quarters.
  • TMD & Associates's Novartis position peaked at $3.17M in Q2 2016.
  • 910 funds tracked by Wall St. Rank held Novartis as of Q1 2017.

Based on TMD & Associates's 13F filing for Q1 2017, filed 26 Apr 2017.